High-Quality STROMUSC RAD140(Testolone)10mg For Bodybuilding CAS:1182367-47-0
In the crowded landscape of performance-enhancing compounds, few substances have generated as much intrigue—and controversy—as RAD140, more commonly known as Testolone. Originally synthesized by Radius Health as a potential therapeutic agent for muscle-wasting conditions and hormone-sensitive breast cancer, this non-steroidal selective androgen receptor modulator (SARM) has been repurposed by the bodybuilding community into one of the most sought-after compounds for lean tissue accrual. But unlike the hyperbolic marketing that surrounds many research chemicals, RAD140's reputation rests on a foundation of genuine pharmacological potency—one that demands respect, rigorous protocol adherence, and a sober understanding of its risks.
What Is RAD140 (Testolone)?
RAD140-development code for the compound vosilasarm-is a nonsteroidal SARM with the molecular formula C₂₀H₁₆ClN₅O₂ and a molecular weight of 393.83 Da. Its chemical architecture features a pyrazolo-quinoline backbone, a structural configuration that confers high androgen receptor binding affinity while maintaining tissue selectivity.
What distinguishes RAD140 from traditional anabolic-androgenic steroids is its mechanism of tissue-specific action. Upon oral administration, RAD140 binds to the androgen receptor (AR) with a Ki of approximately 7 nM-comparable to dihydrotestosterone (1–5 nM) and superior to testosterone's binding affinity (approximately 10 nM). However, unlike testosterone, RAD140 functions as a full agonist in skeletal muscle and bone tissue while exhibiting minimal agonist activity-and in some contexts, antagonist activity-in the prostate, skin, and other androgen-sensitive tissues.
This tissue selectivity is achieved through differential cofactor recruitment: the conformational change RAD140 induces upon AR binding favors interaction with coactivators predominantly expressed in muscle and bone rather than those prevalent in prostate or sebaceous glands. The result is an anabolic-to-androgenic ratio of approximately 90:1-meaning that for every unit of androgenic (masculinizing) effect, RAD140 delivers roughly 90 units of anabolic (muscle-building) effect.
RAD140 is not approved by any regulatory agency for human use. It remains a research compound, and all available product is research-chemical grade. The World Anti-Doping Agency prohibits it under Section S1, with a urine detection window of approximately 21 days.
Key Features of Top-Quality 10mg RAD140
Oral Bioavailability. RAD140 is orally bioavailable, eliminating the need for injections. In animal models, bioavailability ranges from 27–63% in rats to 65–75% in monkeys. This makes once-daily oral administration both practical and effective.
Extended Half-Life. The elimination half-life of RAD140 is approximately 45–60 hours in humans, according to pharmacokinetic data. Some sources cite a half-life of approximately 44.7 hours. Regardless of the precise figure, this extended duration means blood levels accumulate with daily dosing and remain elevated even after cessation.
No Aromatization. RAD140 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase. This eliminates estrogen-related side effects such as water retention and gynecomastia, and reduces the risk of DHT-mediated hair loss and prostate stimulation.
Neuroprotective Properties. Preclinical research has demonstrated that RAD140 crosses the blood-brain barrier and exhibits neuroprotective effects. In cultured hippocampal neurons, RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults, with neuroprotection dependent upon MAPK signaling.
High Androgen Receptor Affinity. With a Ki of approximately 7 nM, RAD140 binds the AR with high affinity, driving robust anabolic signaling through AR-dependent gene transcription pathways involved in protein synthesis, nitrogen retention, and satellite cell proliferation.
Applications in Bodybuilding
The 10mg RAD140 protocol has found its primary application across three distinct bodybuilding contexts:
First Enhanced Cycle. For individuals transitioning from natural training to their first experience with anabolic compounds, 10mg of RAD140 daily represents a common entry point. The compound delivers meaningful anabolic effects without the needle, and the tissue selectivity theoretically reduces the severity of androgenic side effects compared to traditional steroids.
Recomposition. RAD140 at 10mg is frequently employed during body recomposition phases-simultaneous fat loss and muscle gain. Users report a "dry and vascular" appearance, attributable to the compound's lack of water retention and its ability to enhance muscle hardness and definition.
Strength-Focused Blocks. The aggression and drive reported at 10–20mg daily can push personal records significantly, making RAD140 a staple for strength-oriented cycles.
An 8-week cycle at 10mg daily is often cited as the "sweet spot"-long enough to realize meaningful gains but short enough to mitigate the severity of suppression and hepatotoxicity.
Benefits at 10mg Daily
Lean Muscle Accrual. Anecdotal reports suggest users can expect 5–15 pounds of lean muscle mass gains over a 4-to-6-week period at 10mg daily. These gains are characterized as "dry" muscle-dense, hard, and vascular, without the subcutaneous water retention associated with aromatizing compounds.
Strength Enhancement. Strength increases are often reported within the first week of administration. This rapid onset is attributable to the compound's potent AR agonism and the neurological adaptations it facilitates.
Fat Loss. RAD140 has demonstrated fat-reducing properties in preclinical models, and users report a leaning-out effect even during maintenance-calorie phases.
Recovery Acceleration. Enhanced protein synthesis and nitrogen retention translate to improved recovery between training sessions, allowing for higher training frequency and volume.
Dosage and Administration
The 10mg daily dose represents what many consider the conservative starting point for RAD140. More advanced protocols may escalate to 15–20mg, but the 10mg dose is typically recommended for first-time users.
Administration: Oral, once daily. Due to the extended half-life, split dosing is unnecessary-a single daily dose maintains elevated blood serum levels.
Timing: Morning administration is common, though the half-life is sufficiently long that timing is not critical as long as dosing is consistent.
Duration: Cycles typically run 8–12 weeks. Eight weeks is frequently cited as the optimal balance between results and risk mitigation.
The Half-Life: Why It Matters
The half-life of RAD140-approximately 45–60 hours-has profound implications for both cycle design and post-cycle recovery.
Accumulation. With daily dosing, blood levels do not simply reach a steady state and plateau; they accumulate. The long half-life means that by week four of a cycle, circulating concentrations are significantly higher than they were in week one, even at the same daily dose.
Delayed Onset of Effects. Both therapeutic effects and side effects may be delayed in onset. Users may not fully appreciate the compound's impact-or the severity of suppression-until several weeks into a cycle.
Prolonged Clearance. Upon cessation, RAD140 does not clear rapidly. This has implications for when to begin post-cycle therapy; starting PCT too early, while the compound is still actively suppressing the HPTA axis, may be less effective.
Missed Doses. The extended half-life means that missing a single dose does not cause a significant drop in blood levels. Some users even report that dosing every other day is sufficient, though daily administration maintains more consistent levels.
Cycle Protocol: The 10mg Template
A standard 10mg RAD140 cycle follows this structure:
Weeks 1–8: 10mg RAD140 daily, oral administration. Some protocols incorporate a "test base"-typically exogenous testosterone or a SERM run alongside the cycle-to mitigate suppression symptoms. Enclomiphene at 6.25mg every other day, starting around week four, is one common approach.
On-Cycle Support: Liver support (TUDCA 500mg daily) is strongly recommended. Baseline and mid-cycle lipid panels and liver function tests are essential.
Cycle Length Considerations: Extending beyond eight weeks at 10mg increases the depth of HPTA suppression and the risk of hepatotoxicity. The severity of suppression escalates markedly after the six-week point.
Post-Cycle Therapy (PCT)
RAD140 suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. This suppression is dose-dependent and occurs in virtually all users by weeks 4–6. Testosterone, LH, and FSH can be suppressed to near-hypogonadal levels within weeks. Full PCT with a SERM is therefore required.
PCT Initiation: Start PCT 2–3 days after the last RAD140 dose. Some protocols recommend a 5–7 day delay to account for the compound's long half-life.
SERM Options:
Enclomiphene: 12.5–25mg daily for 4–6 weeks. Enclomiphene is increasingly preferred due to its favorable side effect profile-no estrogenic agonist activity (unlike racemic clomifene) and well-tolerated.
Tamoxifen (Nolvadex): 20mg daily for 4 weeks.
Clomiphene (Clomid): 25–50mg daily for 4 weeks.
PCT Duration: A minimum of 4 weeks is standard. Some protocols extend to 6 weeks.
Test Base During Cycle: Some users incorporate enclomiphene during the cycle itself (e.g., 6.25mg every other day from week four) to maintain endogenous testosterone production and mitigate suppression symptoms.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
RAD140; RAD-140; EP0062; testolone,Vosilasarm |
|
CAS |
1182367-47-0 |
|
Molar mass |
393.83 |
|
MF |
C20H16ClN5O2 |
|
Purity |
Above 98% |
|
Apprarance |
10mg*100 |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785
Conclusion
RAD140 at 10mg daily represents a potent pharmacological intervention for lean tissue accrual and performance enhancement. Its tissue selectivity, oral bioavailability, and lack of aromatization confer advantages over traditional androgens. However, its hepatotoxicity, profound HPTA suppression, and the unknown long-term consequences of its use demand a level of caution that the bodybuilding community does not always afford it. The compound is not approved for human use, lacks long-term safety data, and all available product is research-chemical grade.
For those who choose to proceed, the 10mg protocol-8 weeks on, followed by a structured 4-week PCT with enclomiphene or tamoxifen, with rigorous liver and lipid monitoring-represents the most conservative approach. But conservative does not mean safe. It means less dangerous.
The decision to use RAD140 is not one to be made lightly, nor one to be made without comprehensive blood work, a clear understanding of the risks, and an honest assessment of whether the gains justify the potential cost.
Hot Tags: high-quality stromusc rad140(testolone)10mg for bodybuilding cas:1182367-47-0, China high-quality stromusc rad140(testolone)10mg for bodybuilding cas:1182367-47-0 manufacturers, suppliers, factory, GW0742 Hormone and Metabolic Regulators, LGD4033 Treat Muscular Dystrophy and Osteoporosis, OTR AC Gain muscle mass, S23, Sarms S 23 selective androgen receptor modulator, SR9011
